NCT05786430

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 87 (estimated)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This trial is Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients with EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to prior lazertinib.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Lazertinib/Pemetrexed/Carboplatin	Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)

Timeline

• Start date: 2023-04-07
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2023-03-27
• Last updated: 2026-01-27

Locations

1 site across 1 country: South Korea